New drugs are urgently needed for Alzheimer’s disease (AD), especially those that do not target amyloid-β (Aβ) and tau since a variety of those drugs have shown minimal effectiveness in the clinical trials (Polanco et al., 2018; Zhu et al., 2019). Here, MAPT is linked to Alzheimer disease.